Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Hematological disorders

Hematological Disorders

medtech-news-for-siemens-medtronic-jnj

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Siemens Healthineers Acquires Molecular Imaging Division from Novartis; BD and Babson Diagnostics Unveil Fingertip Blood Testing for Health Care; Medtronic Completes First Ingestion of Pillcam™ Genius SB Kit; FDA Expands Impella Heart Pump Use to Pediatric Patients; Zimmer Biomet Receives FDA Nod for OsseoFit™ Stemless System; enVVeno Medical Completes Final Implants in Pre-Clinical GLP Study

Siemens Healthineers Acquired Novartis’s Advanced Accelerator Applications Molecular Imaging On December 10, 2024, Siemens Healthineers completed the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis. This European manufacturing and distribution network specializes in diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. Following the acquisition, the company will operate as Advanced Accelerator Applications, a Siemens Healthineers company. The acquisition enhances Siemens Healthineers’ PETNET Solutions network, which includes 47 PET radio pharmacies in the U.S., by adding 13 manufacturing sites across...

Explore More...

pharma-news-for-applied-therapeutics-alnylam-rigel

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

Pharma-news-for-prolong-shorla-novartis

Prolong’s PP-007 Fast-Tracked for Stroke; FDA Expands JYLAMVO Pediatric Approval; Corcept’s Cushing’s Drug Shows Positive Phase III Results; ESSA Halts Phase II Study of Masofaniten for Prostate Cancer; SCEMBLIX Approved for Leukemia

medtech-news-for-medtronic-abbott-wellsky

Medtronic Secures FDA Green Light for Affera™ Mapping and Ablation System Alongside Sphere-9™ Catheter; Precision Optics Gets FDA 510(k) Clearance; Abbott Launches New Clinical Trial Aimed at Enhancing Care for Advanced Heart Failure Patients; Fresenius Medical Care’s Study Confirms Efficacy of New Anemia Therapy Software in Enhancing Outcomes for Hemodialysis Patients; Inspira™ Announces New Distribution Center to Support INSPIRA™ ART100’s U.S. Introduction; WellSky Expands Home Care Offerings with Acquisition of Bonafide

Pharma-news-for-modalis-pfizer-hibercell

FDA Grants Orphan Status to MDL-101 for LAMA2-CMD; Pfizer’s ABRYSVO Approved for High-Risk Adults (18-59); KIND’s AND017 Gains Orphan Designation for Sickle Cell Disease; HiberCell’s HC-7366 Fast-Tracked for AML; ORLYNVAH Approved for Uncomplicated UTIs

role-of-plasma-protein-therapeutics

Plasma Proteins Therapeutics: Transforming Treatment in Hematology and Beyond

medtech-news-for-establishment-labs-surmodics-medtronic

Establishment Labs Gains FDA Approval for Motiva Implants; Surmodics Receives 510(k) Clearance for Pounce™ XL Thrombectomy System; Synergy Spine Solutions Completes Patient Enrollment in Synergy Disc® 2-Level IDE Clinical Trial; Medtronic Reports Strong Lesion Durability Data for PulseSelect™ Ablation System and Expands AiBLE™ Spine Surgery Ecosystem with Siemens Healthineers Partnership; Globus Medical Launches New Orthopedic Trauma Solutions

Pharma-news-for-bms-intrabio-pfizer

IntraBio’s AQNEURSA Niemann-Pick Disease Approval; FDA Approves Novel Schizophrenia Drug After 35 Years; Selpercatinib Gets FDA Nod for RET-Mutated MTC; DUPIXENT Receives First-Ever COPD Approval; Pfizer Withdraws OXBRYTA for Sickle Cell Disease from Global Market

cd38-directed-therapies-for-multiple-myeloma-treatment

Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

Pharma-news-for-gilead sciences-syndax-astrazeneca

Gilead’s Livdelzi FDA Approval for Primary Biliary Cholangitis; Incyte and Syndax’s Niktimvo Approved for Graft-Versus-Host Disease; FDA Lifts Hold on BioNTech and MediLink’s ADC Cancer Trial; FDA Approves IMFINZI for Resectable Lung Cancer; Yutrepia Receives Tentative Approval for PAH and PH-ILD

pharma-news-for-astrazeneca-ipsen-pfizer

IMFINZI’s AEGEAN Phase III Trial Data for Treating Resectable NSCLC; Ipsen and Day One’s Exclusive Agreement to License and Market Tovorafenib Outside the US; Alzheimer’s Drug LEQUEMBI Rejected by EU; EU Apporves Pfizer’s Gene Therapy DURVEQTIX; CHMP Approves SPEVIGO’s New Indications

The Changing Landscape of Multiple Myeloma Therapies Market

The Changing Landscape of Multiple Myeloma Therapies Market

competitive-analysis-of-celmods-and-revlimid

CELMoDs – A Worthy Successor to REVLIMID?

bms-and-janssen-multiple-myeloma-treatment-drugs-landscape

BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?

bispecific-antibodies-for-multiple-myeloma-treatment

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

myelofibrosis-treatment-landscape

The Dynamic Landscape of Myelofibrosis Treatment: A 2024 Perspective

pharma-news-for-takeda-ac-immune-eli-lilly-bristol-myers-squibb

Takeda and AC Immune’s Alzheimer’s Deal; Eli Lilly’s Donanemab FDA Review; Bristol Myers Squibb’s Phase III CheckMate -73L Trial Result; Regeneron Pharmaceuticals’ Dupixent sBLA; Excision BioTherapeutics’ EBT-101 Phase I/II Trial Results

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly